Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Proper inference from Simon's two-stage designs.

Koyama T, Chen H.

Stat Med. 2008 Jul 20;27(16):3145-54.

PMID:
17960777
2.

Multistage designs for phase II clinical trials: statistical issues in cancer research.

Kramar A, Potvin D, Hill C.

Br J Cancer. 1996 Oct;74(8):1317-20. Review.

3.

Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.

Jung SH.

Contemp Clin Trials. 2015 May;42:9-17. doi: 10.1016/j.cct.2015.02.007. Epub 2015 Mar 3. Review.

4.

Phase II clinical trials in oncology: strengths and limitations of two-stage designs.

Schlesselman JJ, Reis IM.

Cancer Invest. 2006 Jun-Jul;24(4):404-12. Review.

PMID:
16777694
5.

Statistical power and sample size estimation for headache research: an overview and power calculation tools.

Houle TT, Penzien DB, Houle CK.

Headache. 2005 May;45(5):414-8. Review.

PMID:
15953257
6.

Sample size recalculation in internal pilot study designs: a review.

Friede T, Kieser M.

Biom J. 2006 Aug;48(4):537-55. Review.

PMID:
16972704
7.

Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.

Mayo MS, Gajewski BJ.

Control Clin Trials. 2004 Apr;25(2):157-67. Review.

PMID:
15020034
8.

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

El-Maraghi RH, Eisenhauer EA.

J Clin Oncol. 2008 Mar 10;26(8):1346-54. doi: 10.1200/JCO.2007.13.5913. Epub 2008 Feb 19. Review.

PMID:
18285606
9.

Disciplined analyses in clinical trials: the dark heart of the matter.

Moyé LA.

Stat Methods Med Res. 2008 Jun;17(3):253-64. Epub 2007 Oct 9. Review.

PMID:
17925318
10.

Combining proof-of-concept with dose-finding: utilization of adaptive designs in migraine clinical trials.

Sagkriotis A, Scholpp J.

Cephalalgia. 2008 Aug;28(8):805-12. doi: 10.1111/j.1468-2982.2008.01595.x. Epub 2008 May 30. Review.

PMID:
18513264
11.

Sample size for ophthalmology studies.

Naduvilath TJ, John RK, Dandona L.

Indian J Ophthalmol. 2000 Sep;48(3):245-50. Review.

12.

Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.

Halabi S.

Urol Oncol. 2008 May-Jun;26(3):300-7. doi: 10.1016/j.urolonc.2006.11.007. Epub 2007 Nov 19. Review.

PMID:
18452825
13.

Adaptive clinical trials: progress and challenges.

Coffey CS, Kairalla JA.

Drugs R D. 2008;9(4):229-42. Review.

PMID:
18588354
14.

Novel designs and end points for phase II clinical trials.

Adjei AA, Christian M, Ivy P.

Clin Cancer Res. 2009 Mar 15;15(6):1866-72. doi: 10.1158/1078-0432.CCR-08-2035. Epub 2009 Mar 10. Review.

15.

Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.

van der Lee JH, Wesseling J, Tanck MW, Offringa M.

J Clin Epidemiol. 2008 Apr;61(4):324-30. doi: 10.1016/j.jclinepi.2007.07.008. Epub 2008 Feb 21. Review.

PMID:
18313556
16.

Imputation strategies for missing continuous outcomes in cluster randomized trials.

Taljaard M, Donner A, Klar N.

Biom J. 2008 Jun;50(3):329-45. doi: 10.1002/bimj.200710423. Review.

PMID:
18537126
17.

Sampling techniques, confidence intervals, and sample size.

Indrayan A, Gupta P.

Natl Med J India. 2000 Jan-Feb;13(1):29-36. Review. No abstract available.

PMID:
10743375
18.

Supplemental Content

Support Center